Nuvelo has appointed Hana Moran vice president of regulatory affairs and quality assurance.
Moran comes to Nuvelo from Lipid Sciences, where she was vice president of regulatory affairs and quality assurance. Before that she held senior management positions at BioMedicines and SangStat Medical Corp.
Lynx Therapeutics has hired Friedman, Billings, Ramsey & Co. to be its financial advisor. In April 2002, FBR acted as sole manager for an approximately $22.6 million private financing of common stock and warrants for common stock for the struggling gene-expression shop.
“We’ve engaged FBR to help us consider opportunities that may be presented to us,” said Kevin Corcoran, Lynx’s president and CEO. “We believe that our Massively Parallel Signature Sequencing services and related products are poised for significant growth in the gene expression market.”